Plus Therapeutics Provides Business Update on REYOBIQ(TM) Clinical Program and U.S. CNSide® Commercialization

Stock Information for PLUS THERAPEUTICS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PLUS THERAPEUTICS Inc.

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ(TM) for Leptomeningeal Metastases
Plus Therapeutics Expands CNSide Assay Platform to State of California
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Plus Therapeutics Highlights Three REYOBIQ(TM) Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ(TM) in Leptomeningeal Metastases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.